Akari Therapeutics Plc Stock Price, News & Analysis
AKTX
NASDAQ
Company Description
Welcome to the overview page for Akari Therapeutics Plc (AKTX), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
$0.2841
-3.43%
0.01
Last updated: January 6, 2026 at 08:58
-78.68 %
Performance 1 year
$10.4M
45.8M
Latest News
SEC Filings
Financial Highlights
-$2,895,000
Net Income (TTM)
$0.00
-$1,490,000
Operating Cash Flow
0.29
-$2,927,000
—
Revenue (TTM)
Upcoming Events
SEP
01
September 1, 2026 - December 31, 2026
Clinical
First-in-human trial start
AKTX-101 (Trop2 ADC) first-in-human trial initiation expected; protocol/sites TBD
SEP
01
September 1, 2026 - April 30, 2027
Clinical
Phase 1 study start
Planned Phase 1 first-in-human start, subject to regulatory clearance; GMP material via WuXi XDC.
SEP
01
September 1, 2026 - April 30, 2027
Clinical
AKTX-101 clinical start
Planned IND/clinical start window late 2026–early 2027 per company announcement
SEP
01
September 1, 2026 - April 30, 2027
Clinical
Phase 1 trial start
Aiming to submit IND/CTA and start Phase 1 trial late 2026–early 2027, pending clearance.
OCT
01
October 1, 2026 - December 31, 2026
Clinical
AKTX-101 clinical trial start
Trop2-directed ADC; first-in-human clinical trial planned to start in Q4 2026; IND-enabling studies ongoing
JAN
01
January 1, 2027 - December 31, 2027
Clinical
Preliminary safety and efficacy results
Expected preliminary safety and efficacy readout for AKTX-101; topline results anticipated
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Akari Therapeutics Plc (AKTX)?
The current stock price of Akari Therapeutics Plc (AKTX) is $0.2942 as of January 5, 2026.
What is the market cap of Akari Therapeutics Plc (AKTX)?
The market cap of Akari Therapeutics Plc (AKTX) is approximately 10.4M. Learn more about what market capitalization means .
What is the net income of Akari Therapeutics Plc (AKTX)?
The trailing twelve months (TTM) net income of Akari Therapeutics Plc (AKTX) is -$2,895,000.
What is the earnings per share (EPS) of Akari Therapeutics Plc (AKTX)?
The diluted earnings per share (EPS) of Akari Therapeutics Plc (AKTX) is $0.00 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Akari Therapeutics Plc (AKTX)?
The operating cash flow of Akari Therapeutics Plc (AKTX) is -$1,490,000. Learn about cash flow.
What is the current ratio of Akari Therapeutics Plc (AKTX)?
The current ratio of Akari Therapeutics Plc (AKTX) is 0.29, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of Akari Therapeutics Plc (AKTX)?
The operating income of Akari Therapeutics Plc (AKTX) is -$2,927,000. Learn about operating income.